Immune Reconstitution After Allo-HSCT and Blinatumomab
Sichuan University
Sichuan University
Eisai Inc.
National Institutes of Health Clinical Center (CC)
Etablissement Français du Sang
Stanford University
Hoffmann-La Roche
Office of Rare Diseases (ORD)